In the treatment of unresectable HCC with Atezo + Bev or lenvatinib, the dynamics of peripheral blood CD90(+) CTCs were shown to be strongly associated with tumor responsiveness and prognosis, suggesting their potential as valuable biomarkers. Here, THY1 is linked to neoplasm.